Unknown

Dataset Information

0

Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan.


ABSTRACT:

Objectives

Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Serological testing for anti-SARS-CoV-2 nucleocapsid (N) antibodies (Abs) and anti-SARS-CoV-2 spike (S) Abs is performed to detect prior COVID-19 infection. It is still controversial which antibodies are the most sensitive and specific, and which can be detected earliest after infection. Here, we evaluated the results of serological tests of anti-SARS-CoV-2 N and S Abs in Japan.

Methods

Symptomatic COVID-19 patients (n = 84) and control patients with rheumatoid arthritis (n = 93) were recruited at Tokyo National Hospital. Anti-SARS-CoV-2 N and S Abs were measured by commercial electrochemiluminescence immunoassays.

Results

The fraction of patients positive for anti-SARS-CoV-2 N and S Abs was highest >14 days after symptom onset. The frequency of anti-SARS-CoV-2 S Ab positivity at this time (80.4%) tended to be slightly but not significantly lower than anti-SARS-CoV-2 N Ab positivity (84.8%). Optimized cut-off levels for anti-SARS-CoV-2 N and S Ab positivity were lower than the manufacturer's recommended cut-off levels. Using multiple linear regression analyzes with anti-SARS-CoV-2 N and S Abs, we created an Ab-index with high sensitivity.

Conclusion

To increase the sensitivity of serological diagnostic tests for COVID-19, it is suggested that both anti-SARS-CoV-2 N and S Abs should be measured and cut-off levels decreased.

SUBMITTER: Furukawa H 

PROVIDER: S-EPMC8990541 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan.

Furukawa Hiroshi H   Oka Shomi S   Higuchi Takashi T   Yamaguchi Miho M   Uchiyama Shota S   Koiwa Tomohiro T   Nakama Moriyuki M   Minegishi Masaaki M   Nagai Hideaki H   Tohma Shigeto S  

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20220405


<h4>Objectives</h4>Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Serological testing for anti-SARS-CoV-2 nucleocapsid (N) antibodies (Abs) and anti-SARS-CoV-2 spike (S) Abs is performed to detect prior COVID-19 infection. It is still controversial which antibodies are the most sensitive and specific, and which can be detected earliest after infection. Here, we evaluated the results of serological tests of anti-SARS-CoV-2 N and  ...[more]

Similar Datasets

| S-EPMC9144302 | biostudies-literature
| S-EPMC7604306 | biostudies-literature
| S-EPMC7361618 | biostudies-literature
| S-EPMC7782901 | biostudies-literature
| S-EPMC7111193 | biostudies-literature
| S-EPMC9562483 | biostudies-literature
| S-EPMC8837483 | biostudies-literature
| S-EPMC7313936 | biostudies-literature
| S-EPMC8447547 | biostudies-literature
| S-EPMC8320896 | biostudies-literature